Sanofi Invests €1 Billion to Boost Drug Manufacturing in France

14.05.2024 - On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.

The new investment is expected to create more than 500 jobs and significantly strengthen France's ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

In Vitry-sur-Seine, Sanofi wants to invest €1 billion to build a new facility that will double the site's monoclonal antibody production capacity, where several biologics in development amongst Sanofi’s pipeline of drugs for the treatment of chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis or type 1 diabetes, could be produced.

At the Le Trait site in Normandy, Sanofi plans to invest €100 million to expand the capacity for biologics formulation, filling, device assembly and packaging, supporting the launch of future biologics and vaccines, as well as and the further growth of existing biologics production.

In Lyon Gerland, €10 million are to be invested to locate the production of TZield, a biologic for type 1 diabetes that Sanofi acquired in April 2023 and which has been manufactured outside Europe, in France.

Paul Hudson, Sanofi’s CEO, commented: "Thanks to the transformation undertaken since 2020, Sanofi has a record number of medicines and vaccines in development that could become best-in-class and help meet major public health challenges. With these unprecedented industrial investments, we remain true to our history by once again choosing France to produce these future medicines and make them available to patients around the world. France is, and always will be, at the heart of Sanofi's strategy."

"Throughout its history, Sanofi has always sought to equip France with the strategic platforms needed to produce the essential medicines and vaccines of today and tomorrow. This is why we chose our Vitry site to double its monoclonal antibody production capacity, after having already invested heavily in Neuville-sur-Saône to produce our future vaccines, including with mRNA technology. We have also strengthened our API production sites in the south of France. Our contribution to health sovereignty in Europe, and France in particular, has always been and remains unique," said Audrey Derveloy, president of Sanofi France.